Tumor-associated antigens on patient-derived tumor membrane vesicles (TMV) (TMV)

Tumor-associated antigens (TAAs) on patient-derived tumor membrane vesicles (TMVs) represent a personalized approach to cancer immunotherapy [1]. TMVs are extracellular vesicles, such as microvesicles and exosomes, shed by tumor cells into the microenvironment, carrying a diverse array of proteins, lipids, and nucleic acids that reflect the antigenic profile of the parent tumor [2]. In their native state, these vesicles often contribute to tumor progression and immune evasion by delivering immunosuppressive signals, such as PD-L1 or TGF-beta, to the host immune system [2, 3]. However, when isolated and used as a vaccine platform, TMVs serve as a rich source of autologous antigens that can be presented to the immune system to trigger a robust, multi-antigenic T-cell response [1, 4]. This strategy aims to overcome the limitations of single-antigen vaccines by capturing the unique antigenic landscape of an individual's cancer, potentially reducing the risk of immune escape [3, 4]. Clinical applications often involve combining TMV-based vaccines with immune checkpoint inhibitors to enhance the efficacy of the anti-tumor response [4].

Other names

Tumor-derived membrane vesiclesTMVsTumor-derived extracellular vesiclesTEVsAutologous tumor membrane vesiclesTumor cell membrane vesiclesTCMVsTumor-derived microvesicles

The target serves as a source of patient-specific antigens that, when delivered as a vaccine, are processed by antigen-presenting cells to induce a polyclonal cytotoxic T-lymphocyte response against the tumor.